The FDA is set to evaluate potential heart risks linked to the diabetes drug saxagliptin by AstraZeneca. The FDA will consider the issue after the drugmaker submits data from clinical trials, expected by early March. The investigation follows publication of research in the New England Journal of Medicine that revealed saxagliptin-treated patients showed a slight increase in heart failure admissions.

Full Story:

Related Summaries